Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15311172 | 1.00 | KMT2A (0.61) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL7437248 | 1.00 | KMT2A (0.61) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| Hydrochloric Acid SCHEMBL5967355 | 0.98 | KMT2A (0.59) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL10627851 | 0.90 | KMT2A (0.77) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL10423181 | 0.90 | KMT2A (0.77) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL10611159 | 0.90 | KMT2A (0.77) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| Hydrochloric Acid SCHEMBL10632778 | 0.89 | KMT2A (0.74) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL7806373 | 0.87 | KMT2A (0.58) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL7806369 | 0.87 | KMT2A (0.58) | KMT2ACYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL12310885 | 0.87 | KMT2A (0.58) | KMT2ACYP2D6CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996040204-A1 | NOVEL INHIBITORS OF COLLAGENASE-1 AND STROMELYSIN-I METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1996-12-19 | — | — | WO | claimed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
| US-4554100-A | ENZYME INHIBITORS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KMT2A 4608/4885CYP2D6 4715/4885CYP2C9 4341/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | KMT2A 3331/4885CYP2D6 3793/4885CYP2C9 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.